TORRENT PHARMACEUTICALS L vs VIMTA LABS LIMITED
A side-by-side comparison of TORRENT PHARMACEUTICALS L (TORNTPHARM) and VIMTA LABS LIMITED (VIMTALABS) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, TORRENT PHARMACEUTICALS L leads TORNTPHARM vs VIMTALABS on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation22
- Profitability13
- Growth20
- Size & financial health31
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
VIMTALABS takes 3/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
TORNTPHARM takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
TORNTPHARM takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company is expected to give good quarter", "Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
- − ["Stock is trading at 20.4 times its book value", "Promoter holding has decreased over last quarter: -7.53%", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
- + ["Company has reduced debt.", "Company is almost debt free.", "Company has delivered good profit growth of 30.0% CAGR over last 5 years"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.